Neurocrine Biosciences Reports First Quarter 2023 Financial

/PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced its financial results for the first quarter ended March 31, 2023 and provided an...

Related Keywords

United States , Canada , Neurocrine Bioscience , Neurocrine Biosciences , Kevin Gorman , Prnewswire Neurocrine Biosciences Inc , Xenon Pharmaceuticals , Facebook , Linkedin , Twitter , Voyager Therapeutics Inc , Takeda Pharmaceutical Company , Nasdaq , Sosei Group Corporation , Mitsubishi Tanabe Pharma Corporation , Neurocrine Biosciences Inc , First Quarter Net Product Sales , Product Sales Guidance Reiterated , Chief Executive Officer , Product Sales Highlights , Quarter Financial Highlights , Voyager Therapeutics , Updated Operating Expense Guidance , Product Sales , Pipeline Milestones , Adrenal Hyperplasia , Line Registrational Data , Onset Seizure , Line Phase , Major Depressive , Least One Phase , Vesicular Monoamine Transporter , Corticotropin Releasing Factor Type , Sodium Channel , Orphang Protein Coupled , Biosciences Partners , East Asia , Takeda Pharmaceutical Company Limited , Sosei Group , Webcast Today , Quarterly Report , Nc ,